Gastric cancer ranks among the most frequently TP53-mutated solid tumors [19], and in recent years, the anti-VEGFR2 inhibitor Ramucirumab coupled with Paclitaxel has become standard second-line systemic therapy in this lethal disease [20]. The gene discussed is TP53; the disease is gastric cancer.